GYRE THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.66 USD | -1.66% |
|
-7.55% | -58.51% |
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
| 1st Jan change | Capi. | |
|---|---|---|
| -58.51% | 88Cr | |
| +37.76% | 5.25TCr | |
| -7.47% | 3.9TCr | |
| +37.72% | 3.93TCr | |
| +11.93% | 2.62TCr | |
| -11.17% | 2.66TCr | |
| +16.45% | 2.82TCr | |
| +45.05% | 1.42TCr | |
| +33.13% | 1.26TCr | |
| -3.46% | 1.17TCr |
- Stock Market
- Equities
- GYRE Stock
- News Gyre Therapeutics, Inc.
- Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises
